@Zenox what makes you think that they will tell PAR, not that one, this one? I am not saying they can't, but if PAR's submission recommended dosage passes the criteria for safety how can they justify a dosage that isn't part of the trials, or which PAR recommend? To put that another way, i think they are for all practical purposes limited to one of the trial options or whatever PAR propose.
Anyway, i think the key point is we are getting close to following trials having a clear run in respect to dosage leading to DMOAD.
Ann: 2023 Annual Report and Appendix 4E, page-12
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.0¢ |
Change
0.015(6.67%) |
Mkt cap ! $83.98M | |||
| Open | High | Low | Value | Volume |
| 22.5¢ | 24.0¢ | 22.5¢ | $173.6K | 743.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 99346 | 22.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 131244 | 5 |
View Market Depth
| Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |